Patent intelligence · US
US 2016089368
TREATMENT OF MASTOCYTOSIS WITH MASITINIB
TREATMENT OF MASTOCYTOSIS WITH MASITINIB
Patent details — US 2016089368
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 31, 2016
- Expiration
- Mar 26, 2036
- Applicant
- AB SCIENCE [FR]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 095 A I, A61K 31/ 496 A I, A61K/31095
Quick answer
US 2016089368 (TREATMENT OF MASTOCYTOSIS WITH MASITINIB) is held by AB SCIENCE [FR]. Status: granted. Granted Mar 31, 2016. Expires Mar 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AB SCIENCE [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 095 A I, A61K 31/ 496 A I, A61K/31095, A61K/31496, A61K/90053
More from AB SCIENCE [FR]
Related pharmaceutical patents in our USPTO index.
-
CA 3217490
MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION
granted -
CA 3201259
MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
granted -
CA 3174748
UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)
granted -
CA 3168610
MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS SOUFFRANT DE SCLEROSE EN PLAQUES
granted -
EP 3831384
VERWENDUNG VON MASITINIB ZUR BEHANDLUNG VON EOSINOPHILEM ASTHMA
granted -
WO 2021099616
MASITINIB POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE
granted -
CA 3018635
UTILISATION DE MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS ATTEINTS DE SCLEROSE LATERALE AMYOTROPHIQUE
granted -
WO 2017072335
UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted
Frequently asked questions
What is US patent 2016089368?
US 2016089368 (TREATMENT OF MASTOCYTOSIS WITH MASITINIB) is held by AB SCIENCE [FR]. Status: granted. Granted Mar 31, 2016. Expires Mar 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2016089368?
AB SCIENCE [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 2016089368 expire?
Our index shows an expiration date of Mar 26, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.